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1. Introduction 
In the past few years, efforts are being made to unravel the mechanisms endowed with the 
metabolic disturbances associated with obesity that predispose to the metabolic syndrome 
(MetSyn). The special pathogenic role of liver and visceral adipose tissue (VAT) functions 
has been particularly intriguing, and many hypotheses have been advanced to explain this 
association. Tissue-specific actions of glucocorticoids (GCs) go far beyond the circulating 
levels of the hormones and can be controlled by local intracellular enzymes. In the past few 
years, evidence is being gathered not only on the relevance of such enzymes to GC 
physiological actions but also on their involvement in the pathophysiology of certain 
chronic disease states, in which circulating GC levels are not necessarily altered. These 
enzymes are 11ǃ-hydroxysteroid dehydrogenases (11ǃ-HSDs, EC 1.1.1.146) which 
interconvert inactive GCs, such as cortisone and dehydrocorticosterone, and the active 
hormones, cortisol and corticosterone.  
2. Brief overview of the hypothalamus-pituitary-adrenal (HPA) axis 
The regulation of tissue GC levels is critical for the maintenance of homeostasis, playing a 
central role in essential physiological processes, such as stress responses, energy 
metabolism, electrolyte levels, blood pressure, immunity, cell proliferation and 
differentiation and cognitive functions (Atanasov & Odermatt, 2007). Cortisol release by the 
adrenal gland is under the control of the HPA axis. Briefly, corticotrophin releasing 
hormone (CRH) is produced by parvicellular hypothalamic neurons and acts on anterior 
pituitary cells increasing the production and release of adenocorticotrophic hormone 
(ACTH) into the blood stream in a pulsatile fashion and with circadian rhythm: peak in the 
morning and valley later in the afternoon (Gathercole & Stewart, 2010; White B., 2008b). 
Cortisol is synthesized in the cells of the zona fasciculata of the adrenal cortex. Under the 
influence of ACTH, cholesterol esters, stored in the foamy cytoplasm of these cells, are 
unsterified by cholesterol ester hydrolase and converted to cortisol (Tomlinson et al., 2004; 
White B., 2008a). GCs are able to bind and activate GC receptors (GR) and mineralocorticoid 
receptors (MR), which are ligand-regulated nuclear receptors and members of the steroid 
hormone receptor family (Gathercole & Stewart, 2010). Cortisol and the principal GC in 
rodents, corticosterone, are active steroids whereas cortisone and 11-dehydrocorticosterone, 
the latter in rodents, are inactive (Tomlinson et al., 2004). Cortisol is metabolized in the liver 
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through conjugation with glucuronide and sulfate for posterior renal excretion (Tomlinson 
et al., 2004; White B., 2008a). Moreover, in the liver, 5ǂ- and 5ǃ-reductases inactivate cortisol 
and cortisone, in conjunction with 3ǂ-HSD, to tetrahydrometabolites: 5ǂ-tetrahydrocortisol 
(5ǂ-THF), 5ǃ-tetrahydrocortisol (5ǃ-THF) and tetrahydrocortisone (THE) (Campino et al., 
2010).     
3. 11β-HSDs – enzymology, tissue expression and physiological role 
3.1 11β-HSD type 2 (11β-HSD2) 
Because cortisol and aldosterone have the same in vitro affinity for the MR (Gathercole & 
Stewart, 2010), 11ǃ-HSD2, that catalyzes the inactivation of cortisol to inert cortisone, in 
humans, or of corticosterone to 11-dehydrocorticosterone, in rodents, avoids MR actions of 
GCs. 11ǃ-HSD2 was the first isoform to be identified and is a NAD+ dependent 
dehydrogenase. 11ǃ-HSD2 is present in high amounts in the distal convoluted tubule of the 
kidney, colon, salivary and sweat glands as well as in other locations such as the human 
placenta and vascular wall to avoid deleterious actions of active GC overstimulation 
(Anagnostis et al., 2009; Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; Funder et al., 
1988; Gathercole & Stewart, 2010; Palermo et al., 2004). The importance of 11ǃ-HSD2 activity is 
illustrated in the case of congenital deficiency of 11ǃ-HSD2 in humans (Gathercole & Stewart, 
2010; Stewart et al. 1996), transgenic deletion in mice (Kotelevtsev et al., 1999) or by its 
pharmacological inhibition which produces the apparent mineralocorticoid excess (AME) 
syndrome in which the lack of cortisol inactivation in the kidney allows its mineralocorticoid 
action, producing sodium retention, hypertension and hypokalemia, despite normal 
circulating levels of cortisol and an intact HPA axis (Anagnostis et al., 2009; Andrews et al., 
2003; Edwards et al., 1988; Gathercole & Stewart, 2010; Monder et al., 1986; Mune et al., 1995; 
Palermo et al., 2004; Quinkler & Stewart, 2003; Stewart et al., 1996; Walker & Andrew, 2006). 
Thus AME has been considered ‘Cushing’s disease of the kidney’ where there are normal 
circulating levels of cortisol but a tissue-specific excess at the site of MR action (Stewart, 2005).  
3.2 11β-HSD type 1 (11β-HSD1) 
Pre-receptor metabolism of GCs by 11ǃ-HSD1 amplifies intracellular levels of GCs, through 
the reduction of inactive cortisone in humans (11-dehydrocorticosterone in rodents) back 
into active cortisol (corticosterone in rodents) (Anagnostis et al., 2009; Espindola-Antunes & 
Kater, 2007). 11ǃ-HSD1 is mostly expressed in the liver, adipose tissue (AT), bone, lung and 
central nervous system. However, its expression can be present in other tissues including 
pancreas, kidney cortex, adrenal cortex, cardiac myocytes, bone, placenta, uterus, testis, 
oocytes and luteinized glanulosa cells of the ovary, eye, pituitary, fibroblasts and immune, 
skeletal and smooth muscle cells (Anagnostis et al., 2009; Bujalska et al., 1997; Cooper & 
Stewart, 2009; Espindola-Antunes & Kater, 2007; Stewart & Krozowski, 1999; Tomlinson et 
al., 2004; Whorwood et al. 2001). This enzyme is located in the endoplasmic reticulum, 
facing the lumen (Gathercole & Stewart, 2010), where there is a high concentration of 
NADPH owing to the activity of hexose-6-phosphate dehydrogenase (H6PDH), that 
regenerates NADPH from NADP+ (Atanasov et al., 2008; Bujalska et al., 2005; Draper et al., 
2003).  
11ǃ-HSD1 is bidirectional, able to act as both a reductase (activating GCs) and a 
dehydrogenase (inactivating GCs) (Cooper & Stewart, 2009; Tomlinson et al., 2004). 
However, its main function is as a reductase on intact cells such as hepatocytes (Jamieson et 
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al., 1995), myocytes (Whorwood et al., 2001) and adipocytes (Bujalska et al., 2002a; Bujalska 
et al., 2002b), supported by a higher affinity for cortisone than cortisol (Stewart et al., 1994). 
In vitro, when deprived of NADPH regeneration (Seckl & Walker, 2001; Walker & Andrew, 
2006) or in certain physiological or developmental states, it may work as a dehydrogenase. 
For example, in human omental adipose stromal cells, 11ǃ-HSD1 switches from a 
dehydrogenase to a reductase upon differentiation (Bujalska et al., 2002a; Bujalska et al., 
2002b). In the H6PDH null mouse, hepatic or AT, 11ǃ-HSD1 acts mainly as a dehydrogenase 
(Bujalska et al., 2008b; Lavery et al., 2006). Most studies on the regulation of 11ǃ-HSD1 have 
been performed on rodent tissues showing that GCs, CCAAT/enhancer binding proteins, 
peroxisome proliferator-activated receptor (PPAR) agonists and some pro-inflammatory 
cytokines [tumor necrosis factor- (TNF-) and interleukin-1ǃ] increase 11ǃ-HSD1 
expression. On the other hand, growth hormone (via insulin-like growth factor-1) and liver 
X receptor (LXR) agonists inhibit its expression. Some other factors that may influence 11ǃ-
HSD1 expression include sex steroids, insulin and thyroid hormone, but effects vary in 
different tissues and between species (Tomlinson et al., 2004). 
Human 11ǃ-HSD1 congenital deficiency has been described as the apparent cortisone 
reductase deficiency syndrome (Phillipov et al., 1996). The phenotype is related to the lack 
of regeneration of cortisol in peripheral tissues with compensatory activation of the HPA 
axis. This results in increased secretion of androgens by the adrenals, and affected females 
present hirsutism and oligomenorrhea. 11ǃ-HSD1 congenital deficiency does not appear to 
protect against obesity. The syndrome does not seem to arise only from mutations of 
HSD11B1, but rather from the co-inheritance of deleterious mutations in both HSD11B1 and 
H6PDH (Draper et al., 2003), decreasing NADPH supply and switching 11ǃ-HSD1 to the 
dehydrogenase activity (Lavery et al., 2006).  
4. Chronic GC deficiency or excess  
The involvement of GCs in human obesity, particularly visceral obesity, and its related 
metabolic complications, is becoming increasingly evident. As we will discuss further, this is 
evident not only in subjects with disturbances in the HPA axis, but also in conditions where 
tissue GCs are locally modified. To illustrate the first case, two conditions reflect the 
involvement of circulating cortisol on body weight regulation in opposite extremes: Addison's 
disease (hypocortisolism) and Cushing's syndrome (hypercortisolism) (Rutters et al., 2010). As 
to the second case, the clinical entity that aggregates visceral obesity along with several 
metabolic abnormalities in glucose and lipid metabolism as well as in blood pressure, and 
known as the MetSyn (Reaven, 2011), may constitute the best example. Chronically elevated 
GC levels cause obesity, type 2 diabetes mellitus (T2DM), heart disease, mood disorders and 
memory impairments (Wamil & Seckl, 2007). This is demonstrated in Cushing’s syndrome, in 
which elevated GC levels are a result of increased pathological secretion from the adrenal 
cortex (endogenous) or from prolonged anti-inflammatory GC treatment (iatrogenic) (Newell-
Price et al., 2006). A particular case of Cushing’s syndrome is Cushing´s disease that consists of 
hypercortisolism driven by increased ACTH secretion from pituitary adenoma (Cushing, 1932; 
Stewart, 2005). Patients with Cushing’s syndrome are hypertensive, have visceral obesity, 
insulin resistance (IR; 50% develop T2DM or impaired glucose tolerance) and may present 
hepatic steatosis (Stewart, 2005), muscle weakness, dyslipidemia, mood disturbances and 
infertility as well as features more specific to Cushing's syndrome (e.g. easy bruising, facial 
plethora and violaceous striae) (Carroll & Findling, 2010; Newell-Price et al., 2006). 
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The increase of AT in states of GC excess, such as Cushing’s syndrome, may not seem 
straightforward. Indeed, one might predict from cortisol metabolic actions that it would 
increase the availability of energetic substrates, as is seen with its lipolysis-stimulating effects. 
However, in these settings, particularly if there is positive energy balance, the chronic increase 
in GCs is concomitant with the increase in insulin (Dallman et al., 2004). This favors fatty acid 
re-esterification over lipolysis, which, along with pro-adipogenic effects of insulin and GCs 
(Rosen & MacDougald, 2006), increases AT depots. This is seen particularly on VAT depots, 
rather than other AT locations, probably for two reasons: higher expression of GR (Bronnegard 
et al., 1990) and increased reactivation of circulating cortisone due to high 11ǃ-HSD1 
expression and/or activity (Alberti et al., 2007; Simonyte et al., 2009). 
Diagnostic features of GC excess in Cushing's syndrome overlap many of the MetSyn 
components suggesting that GCs may contribute to the pathogenesis of both states 
(Anagnostis et al., 2009; M. Wang, 2011). It has been demonstrated that circulating cortisol 
concentrations are higher in patients with MetSyn compared with healthy subjects, both in 
basal conditions and during dynamic stimulation (Duclos et al., 2005; Misra et al., 2008; 
Phillips et al., 1998; Sen et al., 2008; Weigensberg et al., 2008). Furthermore, increased 11ǃ-
HSD1 activity in VAT may generate increased cortisol levels within AT and liver and 
thereby promote features of the MetSyn (Walker & Andrew, 2006). This effect has been 
termed ‘Cushing’s disease of the omentum’ (Bujalska et al., 1997; Stewart, 2005).  
5. MetSyn definition 
In the past few decades, there has been a worldwide increase in the prevalence of obesity 
and associated metabolic disorders including glucose intolerance, IR, dyslipidemia and 
hypertension. In the clinical practice, the presence of these conditions defines the MetSyn, 
which comprises an increased risk of atherosclerotic cardiovascular events and T2DM (or is 
associated with T2DM) and, additionally, is characterized by a pro-inflammatory and a pro-
thrombotic state and occurrence of non-alcoholic fatty liver disease (NAFLD) (Feldeisen & 
Tucker, 2007; Gathercole & Stewart, 2010; Johnson & Weinstock, 2006; Reaven, 2011). 
Distinct organizations have established their own definitions of the MetSyn: the World 
Health Organization (WHO), in 1998, the Adult Treatment Panel III (ATP III) of the National 
Cholesterol Education Program (NCEP), in 2001 (updated in 2005), and the International 
Diabetes Federation (IDF), in 2005 (Johnson & Weinstock, 2006; Reaven, 2011). In the 
attempt to harmonize MetSyn definitions, ATP III and IDF, joined by several other 
prestigious organizations, reviewed the criteria. Meeting any three of the following criteria is 
sufficient for the diagnosis: elevated waist circumference (abdominal obesity), triglycerides, 
blood pressure and fasting glucose (glucose intolerance) and low HDL-cholesterol levels. 
The cut points for an elevated waist circumference are not the same for all population 
groups (with population-specific reference values) and drug treatment is sufficient to meet 
the criteria for the other four components. The latest WHO report states that the ‘MetSyn 
should not be a clinical diagnosis’, but rather viewed as ‘a pre-morbid condition, and should 
thus exclude individuals with established T2DM or cardiovascular disease’ (Reaven, 2011). 
6. 11β-HSD1 and MetSyn components: evidence from human and animal 
studies 
Evidence has been accumulated that strongly argues for an etiological role of 11ǃ-HSD1 in 
obesity, T2DM and MetSyn (Cooper & Stewart, 2009; Gathercole & Stewart, 2010; London & 
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Castonguay, 2009; Masuzaki & Flier, 2003; Morton, 2010; Staab & Maser, 2010; Tomlinson & 
Stewart, 2007; van Raalte et al., 2009; Wamil & Seckl, 2007).  
Initial studies in obese humans, that measured the ratio of cortisol to cortisone metabolites in 
urine as an indirect index of total body 11ǃ-HSD activity, produced inconsistent results (such 
ratios, however, are inadequate as they may be influenced by other enzymes involved in 
cortisol metabolism). Recently, more trustworthy results from various more tissue-specific 
measures were obtained (Andrews et al., 2002; Andrews et al., 2003; Desbriere et al., 2006; 
Gathercole & Stewart, 2010; Karlsson et al., 2010; Morton, 2010; Paulmyer-Lacroix et al., 2002; 
Rask et al., 2001; Rask et al., 2002; Sandeep et al., 2005; Stewart & Tomlinson, 2009; R.  Stimson 
et al., 2011; Tomlinson et al., 2008; Valsamakis et al., 2004; Wamil & Seckl, 2007). After studies 
in men and women, representing a wide range of body compositions and insulin sensitivities 
(but without T2DM), 11ǃ-HSD1 activity is found selectively increased in the abdominal 
subcutaneous AT (SAT) in obese humans (Rask et al., 2001; Rask et al., 2002; Sandeep et al., 
2005), to a similar degree as the increase in transgenic overexpressing mice (Andrews et al., 
2003), but impaired in the liver (Rask et al., 2001; Rask et al., 2002; Stewart et al., 1999). This 
decrease in hepatic tissue may represent a compensatory mechanism to preserve insulin 
sensitivity and to decrease hepatic glucose output (Gathercole & Stewart, 2010; Morton, 2010; 
Valsamakis et al., 2004; Wamil & Seckl, 2007). Increased adipose 11ǃ-HSD1 activity results 
from increased 11ǃ-HSD1 mRNA expression (Desbriere et al., 2006; Paulmyer-Lacroix et al., 
2002) in the abdominal SAT in adipocytes, and also in the VAT in both adipocytes and stroma 
(Paulmyer-Lacroix et al., 2002). Valsamakis et al. report a lack of inhibition of 11ǃ-HSD1 
activity with increasing body mass index (BMI) in diabetic patients versus non-diabetic BMI- 
and age-matched controls (where the inhibition is closely associated with VAT mass), and 
suggest that a reduction in 11ǃ-HSD1 activity might act as an autocrine protective mechanism 
to prevent increasing adiposity and increased hepatic glucose output with advancing obesity. 
This adaptive mechanism of reduced cortisol regeneration does not occur in obesity-associated 
T2DM and might contribute to the underlying pathogenesis of the disease (Gathercole & 
Stewart, 2010; Morton, 2010; Valsamakis et al., 2004; Wamil & Seckl, 2007). In contrast, in lean 
patients with T2DM (controlled by diet alone) a relatively small decrease in hepatic 11ǃ-HSD1 
activity, and no change in gluteal SAT enzyme activity, has been reported, but only by one 
group (Andrews et al., 2002; Andrews et al., 2003). Abdominal SAT 11ǃ-HSD1 expression is 
higher in obese women with impaired glucose tolerance than in obese women with normal 
glucose tolerance, despite AT (total and regional) being similar between the two groups, and 
positively correlated with glucose area under curve levels across an oral glucose tolerance 
testing (Tomlinson et al., 2008). Whole-body 11ǃ-HSD1 activity is increased in obese men with 
T2DM, compared to healthy normal-weight control subjects, whereas liver 11ǃ-HSD1 activity 
is sustained, unlike in euglycemic obesity (R.  Stimson et al., 2011). The evidences presented 
raise the hypothesis that hepatic 11ǃ-HSD1 inhibition in obese people who develop impaired 
glucose tolerance may protect from progression to T2DM (Gathercole & Stewart, 2010; Morton, 
2010; Wamil & Seckl, 2007). Additionally, in line with this, myotubes established from obese 
T2DM subjects show an increased expression of 11ǃ-HSD1 mRNA compared to healthy obese 
subjects (Abdallah et al., 2005). SAT 11ǃ-HSD1 mRNA levels decrease during very low calorie 
diet (16 weeks) and anthropometric measurements and metabolic parameters are associated 
with 11ǃ-HSD1 mRNA levels in obese subjects without the MetSyn (following the WHO 
definition). However, in obese subjects with the MetSyn these associations were lost or in the 
opposite direction. In another cohort, this difference is also observed in skeletal muscle (vastus 
lateralis) between subjects with T2DM or with normal glucose tolerance (Karlsson et al., 2010).  
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6.1. Findings of 11β-HSD1 biology from rodent models 
6.1.1 The aP2-HSD11B1 transgenic rodent model 
Transgenic mice with 2–3-fold overexpression of 11ǃ-HSD1, comparable to that seen in 
obese humans, in white AT have been generated, exploiting the murine adipocyte fatty acid 
binding protein (aP2) promoter. These aP2-HSD11B1 transgenic mice have elevated 
corticosterone levels in the AT, but unaltered systemic plasma concentrations, and many 
features of the MetSyn: glucose intolerance and IR [exacerbated further by high-fat (HF) 
feeding], dyslipidemia, apparent leptin resistance, truncal obesity and hypertension 
associated with activation of the circulating renin-angiotensin system. 11ǃ-HSD1 expression 
correlates strongly and positively with adipocyte size (London & Castonguay, 2009; 
Masuzaki & Flier, 2003; Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010; Staab & 
Maser, 2010; van Raalte et al., 2009; Wamil & Seckl, 2007). TNF- and leptin are elevated 
whereas resistin and insulin-sensitizing adiponectin are reduced. aP2-HSD11B1 transgenic 
mice are hyperphagic and obese, predominantly in the VAT. Expression of the GR-ǂ is 
higher in VAT compared to SAT, while the expression of the transgene HSD11B1 is similar 
in all AT depots. The greater effects in VAT may reflect the higher GR and/or higher 
lipoprotein lipase in mesenteric AT. aP2-HSD11B1 transgenic mice have elevated 
corticosterone and free fatty acids (FFA) levels in the hepatic portal vein that drains blood 
from VAT to the liver (Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010; Wamil & 
Seckl, 2007). The aP2-HSD11B1 model shows that altered AT metabolism of GCs (similar to 
human MetSyn levels) could be the primary driver of many features of this disease 
(Masuzaki & Flier, 2003; Masuzaki et al., 2001; Masuzaki et al., 2003; Morton, 2010).  
6.1.2 The apolipoprotein E (apoE)-HSD11B1 transgenic rodent model 
To examine the impact of elevated liver GCs, mice overexpressing 11ǃ-HSD1 selectively in 
that tissue under the control of the human apoE promoter have been generated. Transgenic 
lines with 2- and 5-fold-elevated 11ǃ-HSD1 activity exhibit unaltered systemic 
corticosterone, modest IR (but lacking glucose intolerance), unaltered AT mass (lacking 
obesity or central adiposity), hepatic fat accumulation (mainly as triglycerides) and 
dyslipidemia (elevated circulating FFA and HF diet-induced dyslipidemic cholesterol 
lipoprotein profile), with increased hepatic lipid synthesis/flux associated with elevated 
hepatic LXR-ǂ and PPAR-ǂ expression as well as impaired hepatic lipid clearance. Increased 
expression of GC-inducible cholesterol 7ǂ-hydroxylase present in apoE-HSD11B1 transgenic 
livers may drive increased bile acid synthesis, contributing to stimulation of LXR-ǂ-
regulated pathways (and further potentiation of cholesterol 7ǂ-hydroxylase expression) as 
well as PPAR-ǂ. ApoE-HSD11B1 transgenic mice also have a marked, transgene-dose-
associated hypertension, paralleled by incrementally increased liver angiotensinogen 
expression. Elevated 11ǃ-HSD1 hepatic expression may relate to the pathogenesis of specific 
fatty liver, insulin-resistant and hypertensive syndromes without obesity in humans as may 
occur in, possibly, the metabolically obese normal-weight individual (Paterson et al., 2004). 
6.1.3 The HSD11B1 knockout (KO) rodent model 
HSD11B1 KO mice have been generated, which are viable and healthy but unable to convert 
inert 11-dehydrocorticosterone to corticosterone. Despite compensatory adrenal hyperplasia 
and increased adrenal secretion of corticosterone, on fasting, HSD11B1 KO mice have 
attenuated activation of the hepatic gluconeogenic enzymes, presumably, because of relative 
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intra-hepatic GC deficiency. The HSD11B1 KO mice resist hyperglycemia provoked by 
obesity or stress (Kotelevtsev et al., 1997). HSD11B1 KO mice, fed ad lib, have markedly 
lower plasma triglyceride levels, driven by increased hepatic expression of enzymes of fat 
catabolism and PPAR-ǂ. HSD11B1 KO mice also have increased plasma HDL-cholesterol, 
with elevated liver mRNA and serum levels of apoAI. Conversely, hepatic Aǂ-fibrinogen 
expression is decreased. Upon fasting, the normal elevation of hepatic PPAR-ǂ mRNA is lost 
in HSD11B1 KO mice, consistent with attenuated GC induction. Despite this, crucial 
oxidative responses to fasting are maintained. Refeeding (4 h and/or 24 h) shows more 
rapid and/or marked induction of genes encoding lipogenic enzymes/transcription factors 
and a more rapid and/or marked suppression of genes for fat catabolism in HSD11B1 KO 
mice, implying increased liver insulin sensitivity. PPAR-ǂ is suppressed by 4 h of refeeding 
(similarly in wild type and HSD11B1 KO mice), but PPAR-ǂ levels are higher after 24 h of 
refeeding in HSD11B1 KO mice when compared to wild type mice, reestablishing the ad lib-
fed pattern. Concordant with this, 24 h refed HSD11B1 KO mice have higher plasma 
triglycerides than 24 h refed wild type mice and ad lib-fed HSD11B1 KO mice.  24 h Refed 
HSD11B1 KO mice have lower plasma glucose levels than 24 h refed wild type mice and ad 
lib-fed HSD11B1 KO mice. HSD11B1 KO mice also have improved glucose tolerance. 11ǃ-
HSD1 deficiency may produce an improved lipid profile, hepatic insulin sensitization and a 
potentially atheroprotective phenotype (Morton et al., 2001). HSD11B1 KO mice on the 
control diet express, compared to wild-type mice, lower leptin, resistin and TNF- but 
higher PPAR-, adiponectin and uncoupling protein-2 (UCP-2) mRNA levels in epididymal 
AT, indicating insulin sensitization. On the control diet, in mesenteric VAT, PPAR- mRNA 
is elevated in HSD11B1 KO mice, though leptin, resistin, TNF-, adiponectin and UCP-2 
mRNA levels are unaltered, compared to wild-type mice. With HF feeding, the elevated 
PPAR-Ǆ mRNA level in control-fed HSD11B1 KO mice is further increased selectively in 
VAT, what does not happen in the epididymal AT depot of HSD11B1 KO or wild-type mice. 
HSD11B1 KO mice also show a HF–mediated induction of UCP-2 selectively in VAT, which 
is greater than that observed in wild-type mice. Isolated adipocytes from HSD11B1 KO mice 
exhibit higher basal and insulin-stimulated glucose uptake. HSD11B1 KO mice also display 
reduced VAT accumulation upon HF feeding. HF-fed HSD11B1 KO mice rederived onto the 
C57BL/6J strain (obesity/T2DM/metabolic disease-susceptible) resist T2DM and weight 
gain despite consuming more calories. These data provided the first in vivo evidence that AT 
11ǃ-HSD1 deficiency beneficially alters AT distribution and function (Morton et al., 2004), 
complementing the just above-described effects of hepatic 11ǃ-HSD1 deficiency or data 
presented further bellow regarding 11ǃ-HSD1 pharmacological inhibition. Since PPAR-Ǆ 
ligands cause insulin sensitization and AT redistribution to the periphery, a mechanism for the 
beneficial AT redistribution is suggested, on the assumption that increased circulating FFA 
during HF feeding act as endogenous ligands for PPAR-Ǆ receptors. Further, UCP-2 levels are 
higher in HSD11B1 KO mice AT, consistent with GC and PPAR-Ǆ regulation. This higher 
PPAR-Ǆ-responsive UCP-2 expression in HSD11B1 KO mice AT may drive increased energy 
dissipation within the adipocytes (Morton, 2010). Interestingly, when mice are fed a HF diet 
they preferentially gain weight in peripheral AT rather than in VAT what can be explained by 
an increased expression of PPAR-Ǆ and UCP-2 in VAT (Morton, 2010; van Raalte et al., 2009; 
Wamil & Seckl, 2007).  
Mice overexpressing the cortisol inactivating enzyme specifically on the AT (aP2-HSD11B2 
mice) are phenotypically similar to HSD11B1 KO mice, exception only for food intake, what 
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emphasizes the importance of AT as a target for enzyme inhibition (Wamil & Seckl, 2007). 
11ǃ-HSD1 gene deficiency is associated with a number of improvements of adipose and 
hepatic functions, what highlights the importance of adipose and hepatic 11ǃ-HSD1 in the 
development of metabolic disease.  
6.2 11β-HSD1 and T2DM/IR 
A role for 11ǃ-HSD1 in exacerbating IR and T2DM has been proposed. Animals with 
targeted deletion of HSD11B1 manifest increased hepatic and adipose insulin sensitivity 
(Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004), and when backcrossed onto 
the C57BL/6J strain appear to resist the development of IR in response to HF feeding 
(Morton et al., 2004). Additionally, specific 11ǃ-HSD1 inhibitors improve insulin sensitivity 
(glycemic control and/or glucose and/or insulin levels) in animal models (associated or not 
with HF feeding) of hyperglycemia, obesity (by damage of feeding center or diet-induced), 
T2DM (also ob/ob) and combined T2DM, dyslipidemia and atherosclerosis (Alberts et al., 
2002; Alberts et al., 2003; Barf et al., 2002; Gathercole & Stewart, 2010; Hermanowski-
Vosatka et al., 2005; Morgan et al., 2009; Park et al., 2011; X. Zhang et al., 2009b). 
It is well known that excess GCs increase IR and can, in susceptible individuals, precipitate 
T2DM. In line with this, it has been suggested that the increased production of cortisol from 
VAT seen in obesity could drain through the portal circulation to the liver and pancreas 
contributing to IR (Cooper & Stewart, 2009; Masuzaki et al., 2001; Morton, 2010; R. Stimson et 
al., 2009; Walker & Andrew, 2006; Wamil & Seckl, 2007). This hypothesis was investigated in 
vivo in humans by Stimson et al. by quantifying, for the first time, selectively, the contributions 
of SAT, visceral tissues and liver to whole-body cortisol production by 11ǃ-HSD1. Stimson et 
al. confirmed that splanchnic cortisol production is substantial, originating entirely from the 
11ǃ-HSD1 activity in the liver. However, although release of cortisol by 11ǃ-HSD1 into the 
portal vein, which drains a number of visceral organs, is not detected, a significant cortisol 
release into veins draining exclusively SAT has been found. So, cortisol release from SAT into 
the systemic circulation is unlikely to have effects in other organs because the feedback control 
by the HPA axis will adjust adrenal cortisol secretion to maintain circulating cortisol 
concentrations. Therefore, the most likely impact of this source of cortisol will be intracrine or 
paracrine in the local AT environment (R. Stimson et al., 2009). 
Skeletal muscle represents a key target tissue for insulin-stimulated glucose uptake, 
metabolism and utilization (Abdul-Ghani & DeFronzo, 2010; Benito, 2011; Van Cromphaut, 
2009). There are just a few studies regarding 11ǃ-HSD1 in skeletal muscle from T2DM, 
although with non-consensual results (Cooper & Stewart, 2009). Whorwood et al. found, 
with kinetic analysis, that 11ǃ-HSD1, in intact cultured human skeletal myoblasts (from both 
lean-moderately overweight and obese adult men, few with T2DM but without therapy), 
acts exclusively as a reductase and is down-regulated by insulin, which may maintain 
insulin sensitivity in skeletal muscle tissue by diminishing GC antagonism of insulin action 
(Whorwood et al., 2001). Cortisone reduces glucose uptake in myotubes established from 
obese T2DM men (treated either by diet alone or in combination with sulfonylurea or 
metformin, withdrawn one week before performing the biopsy), what could be mediated by 
an increased mRNA 11ǃ-HSD1 expression (previously mentioned) emphasizing that the 
local conversion of inactive to active GCs may be important in IR pathogenesis (Abdallah et 
al., 2005). Accordingly, Zhang et al., in an animal model of T2DM (Wistar rats with HF 
feeding, combined with multiple low dose streptozotocin injection), report increased 11ǃ-
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HSD1 mRNA and protein levels in skeletal muscle extracts of the diabetic animals versus the 
non-diabetic animals, what may be related to disturbances in insulin signaling pathway 
observed in the skeletal muscle (M. Zhang et al., 2009a). Jang et al. demonstrated that the 
activities of skeletal muscle 11ǃ-HSD1 and 11ǃ-HSD2 (in vastus lateralis biopsies) are 
altered in T2DM patients (treated by diet alone or oral hypoglycemic agents) versus healthy 
age- and sex-matched controls (altogether overweight and obese subjects): 11ǃ-HSD1 
activity is reduced and 11ǃ-HSD2 activity is higher in T2DM subjects (negative correlation 
between both enzyme activities; with similar mRNA levels in T2DM and control subjects for 
both enzymes), and, more importantly, 11ǃ-HSD1 reductase activity is significantly lower in 
T2DM subjects whereas 11ǃ-HSD1 dehydrogenase activity is significantly higher in the 
T2DM group (with very low levels of 11ǃ-HSD1 dehydrogenase activity in both groups). 
Together these results may indicate a reduced intracellular cortisol generation, potentially 
conferring metabolic protection (Jang et al., 2007). In what regards the AT, Balachandran et 
al. demonstrated that insulin stimulates adipocyte 11ǃ-HSD1 activity and expression both in 
vitro (in 3T3-L1 adipocytes) and in vivo (Wistar rat white AT) (Balachandran et al., 2008). 
Morgan et al. established a strong connection between a key player in insulin signaling, the 
insulin receptor substrate 1 (IRS1), and 11ǃ-HSD1 in skeletal muscle: in KK/Ta Jcl mice (an 
hyperglycemic model) treated with A2, inducing selective 11ǃ-HSD1 inhibition, skeletal 
muscle pSer307IRS1 decreases, pThr308Akt/PKB increases and lipogenic and lipolytic gene 
expression decreases (Morgan et al., 2009). 11ǃ-HSD1 has also been proposed to have effects 
on insulin secretion itself. Davani et al. report 11ǃ-HSD1 mRNA expression in human and 
ob/ob mice (non-insulin-dependent diabetes model) pancreatic ǃ-cells, and also characterize 
the 11ǃ-HSD1 activity in intact pancreatic rodent islets (where the reductive reaction 
prevails). In ob/ob mice islets, in the absence of carbenoxolone, 11-dehydrocorticosterone 
markedly inhibits insulin release, whereas a reversal of this effect is noted in the presence of 
carbenoxolone, indicating an important role of 11ǃ-HSD1 in the regulation of insulin release 
(Davani et al., 2000). A more recent report describes a similar effect of dehydrocorticosterone 
on insulin release in human and murine pancreatic cells, but it appears that enzyme 
expression is absent in ǃ-cells, with this effect being mediated indirectly through expression 
within ǂ-cells. This ǂ-cell expression additionally inhibits insulin-stimulated glucagon 
secretion (Cooper & Stewart, 2009; Swali et al., 2008). 
6.3 11β-HSD1 and hypertension 
GC hormones act on the cardiovascular system (Nussinovitch et al., 2010; Raff & Findling, 
2003; Walker et al., 2000; Wallerath et al., 1999). Cortisol and 11ǃ-HSDs have been 
implicated in hypertension (Anagnostis et al., 2009; Andrews et al., 2003; Campino et al., 
2010; Cicala & Mantero, 2010; Edwards et al., 1988; Ferrari, 2010; Franks et al., 2004; 
Funder et al., 1988; Gathercole & Stewart, 2010; Y. Liu et al., 2008; Malavasi et al., 2010; 
Masuzaki et al., 2003; Millis, 2011; Monder et al., 1989; Morales et al., 2008; Mune et al., 
1995; Palermo et al., 2004; Paterson et al., 2004; Quinkler & Stewart, 2003; Raff & Findling, 
2003; S. Shah et al., 2011; Stewart et al., 1996; Walker & Andrew, 2006; Walker et al., 1993; 
Wallerath et al., 1999; White et al., 1997). 
The fact that 11ǃ-HSD2 is important in protecting MR in the distal nephron from stimulation 
by GCs revealed its role in the regulation of arterial blood pressure. Pharmacological 
inhibition or genetic deficiency of 11ǃ-HSD2 leads to the development of hypertension 
(Anagnostis et al., 2009; Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; Funder et 
al., 1988; Gathercole & Stewart, 2010; Palermo et al., 2004; Walker et al., 1993; White et al., 
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1997). HSD11B2 can be epigenetically regulated, what is also involved in hypertension 
development (Millis, 2011). In the same line, defects and polymorphisms in HSD11B2 have 
also been shown to play a role in human hypertension and cardiovascular disease [e.g. 
essential hypertension (Soro et al., 1995; Walker et al., 1993) and ‘salt-sensitive’ hypertension 
(Lovati et al., 1999)] (Bailey et al., 2008; Cooper & Stewart, 2009; Henschkowski et al., 2008). 
Campino et al. reported a high percentage of alterations in the cortisol metabolism at the 
pre-receptor level in hypertensive patients, previously misclassified as having essential 
hypertension, where 18% of the patients present reduced 11ǃ-HSD2  activity or imbalance of 
11ǃ-HSD1 activity in comparison to 11ǃ-HSD2 (Campino et al., 2010). As referred above, 
hypertension is induced in mice genetically modified to overexpress 11ǃ-HSD1 either in the 
liver or AT (Masuzaki et al., 2003; Paterson et al., 2004). HSD11B1 polymorphisms have been 
described, affecting enzyme expression and activity in vitro and/or in vivo, and/or being 
associated with hypertension (Franks et al., 2004; Malavasi et al., 2010; Morales et al., 2008). 
Variants of HSD11B1 were associated with the risk of hypertension in Pima Indians (Franks 
et al., 2004). Liu et al. showed that suppression of 11ǃ-HSD1 expression in the renal medulla 
attenuates salt-induced hypertension in Dahl salt-sensitive rats (Y. Liu et al., 2008). Taking 
into consideration that diet is one important factor on MetSyn development, it is interesting 
to mention that in Dahl salt-sensitive hypertensive rats, fed a high-salt diet for 4 weeks, peri-
renal AT corticosterone concentration and 11ǃ-HSD1 activity as well as GR, 11ǃ-HSD1 and 
TNF-ǂ expression increase when compared with Dahl salt-resistant rats fed the same diet 
(Usukura et al., 2009).  
6.4 11β-HSD1 and NAFLD 
NAFLD is being increasingly recognized as a common liver disorder that represents the 
hepatic manifestation of the MetSyn. NAFLD is more frequent among people with T2DM 
and obesity, and it is almost universal amongst T2DM patients who are morbidly obese 
(Bellentani et al., 2000; Fabbrini et al., 2010; Gupte et al., 2004; Konopelska et al., 2009; Ratziu 
et al., 2010; Wree et al., 2010). Non-alcoholic steatohepatitis (NASH) is the progressive form 
of liver injury that carries a risk of progressive fibrosis, cirrhosis and end-stage liver disease. 
There is strong evidence that IR and increased FFA are a major cause of NASH (Brunt, 2004; 
Konopelska et al., 2009; Ratziu et al., 2010; Scheen & Luyckx, 2002). Inflammation plays an 
important additional role with increased production of reactive oxygen species and pro-
inflammatory cytokines. In addition, several studies support a link between VAT and 
NASH (Kern et al., 2003; Konopelska et al., 2009; McCullough & Falck-Ytter, 1999). 
Konopelska et al., for the first time in patients with elevated liver enzymes (that after liver 
biopsies had histological diagnosis of normality, steatosis, NASH and other forms of 
hepatitis or cirrhosis), found no association between increased liver fat accumulation or 
different stages of liver inflammation and hepatic 11ǃ-HSD1 expression, suggesting that, 
probably, there is no major role of this enzyme in the inflammatory process from fatty liver 
to NASH in humans (Konopelska et al., 2009). In contrast, as mentioned before, transgenic 
mice with hepatic overexpression of 11ǃ-HSD1 develop fatty liver and dyslipidemia 
(Paterson et al., 2004). 11ǃ-HSD1 expression correlated positively with H6PDH expression in 
the liver and negatively with waist-to-hip ratio in women (this being in accordance to 
obesity results we have mentioned previously). No evaluation of 11ǃ-HSD1 and H6PDH 
protein or activity levels was done (Konopelska et al., 2009). 
Given all the above evidences, 11ǃ-HSD1 has thus emerged as a major potential drug target 
for the treatment of obesity and its associated metabolic abnormalities.  
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7. 11β-HSD1 inhibition studies  
Several and distinct selective 11ǃ-HSD1 inhibitors are being produced, developed and tested 
in vitro, ex vivo and in vivo, in normal animals, rodent models of metabolic alterations or 
disease (hyperglycemia, dyslipidemia, atherosclerosis, IR, T2DM, obesity, diet-induced 
obesity and/or MetSyn) and some of them already in humans, healthy or not (Alberts et al., 
2002; Alberts et al., 2003; Barf et al., 2002; Bhat et al., 2008; Bujalska et al., 2008a; Cho et al., 
2009; Cooper & Stewart, 2009; Coppola et al., 2005; Courtney et al., 2008; Feig et al., 2011; 
Gathercole & Stewart, 2010; Ge et al., 2010; Hale et al., 2008; Hale & Wang, 2008; 
Hermanowski-Vosatka et al., 2005; Hollis & Huber, 2011; Hughes et al., 2008; Hult et al., 
2006; Johansson et al., 2008; Julian et al., 2008; J. Liu et al., 2011; Morgan et al., 2009; Morgan 
& Tomlinson, 2010; Morton, 2010; Park et al., 2011; Rosenstock et al., 2010; S. Shah et al., 
2011; U. Shah et al., 2010; Siu et al., 2009; Stewart & Tomlinson, 2009; Tiwari, 2010; Tu et al., 
2008; van Raalte et al., 2009; Véniant et al., 2010; S. J. Wang et al., 2006; Webster et al., 2010; 
Yuan et al., 2007; X. Zhang et al., 2009b). Besides inhibition of 11ǃ-HSD1 reductase activity, 
increase of 11ǃ-HSD1 dehydrogenase (oxidase) activity, without inhibition of 11ǃ-HSD2, 
may provide a better therapeutic strategy for T2DM, obesity and MetSyn (Ge et al., 2010). 
11ǃ-HSD1 is also inhibited by natural compounds, such as an active ingredient of various 
Chinese herbs (emodin), derivatives or analogues of the licorice root, coffee extract,  
flavanone (and the monohydroxylated flavonoid 2′-hydroxyflavanone), endogenous 
steroids and their metabolites and bile acids (Andrews et al., 2003; Atanasov et al., 2006; 
Chalbot & Morfin, 2006; Classen-Houben et al., 2009; Diederich et al., 2000; Feng et al., 2010; 
Gathercole & Stewart, 2010; Hollis & Huber, 2011; Latif et al., 2005; Livingstone & Walker, 
2003; Maeda et al., 2010; Monder et al., 1989; Morris et al., 2004; Odermatt & Nashev, 2010; 
Sandeep et al., 2005; Schweizer et al., 2003; Su et al., 2007; Taylor et al., 2008; Tomlinson et 
al., 2007; van Raalte et al., 2009; Walker et al., 1995a; Wamil & Seckl, 2007). Glycyrrhetinic 
acid, the active pharmacological ingredient of the licorice root and some of its derivatives, as 
well as its steroidal synthetic analogue carbenoxolone (hemisuccinate derivative of 
glycyrrhetinic acid) are inhibitors of both 11ǃ-HSD1 and 11ǃ-HSD2 (the magnitude of the 
effect being dependent on in vitro versus in vivo environment, dose, administration mode, 
tissue and specie as well as compound structure) (Abdallah et al., 2005; Andrews et al., 2003; 
Classen-Houben et al., 2009; Gathercole & Stewart, 2010; Hollis & Huber, 2011; Jellinck et al., 
1993; Livingstone & Walker, 2003; Monder et al., 1989; Sandeep et al., 2005; Su et al., 2007; 
Taylor et al., 2008; Tomlinson et al., 2007; van Raalte et al., 2009; Walker et al., 1995a; Wamil 
& Seckl, 2007). Both 7-oxygenated steroids and 7-ketocholesterol modulate 11-HSD1 activity 
(Balázs et al., 2009; Odermatt & Nashev, 2010; Wamil et al., 2008; Wamil & Seckl, 2007). 
From all the bile salts tested in vitro and found to inhibit 11ǃ-HSD1, Diederich et al. reported 
that chenodesoxycholic acid does not affect in vivo the activity of 11ǃ-HSD1 when given in 
therapeutic doses to healthy men (Diederich et al., 2011).  
7.1 Human 11β-HSD1 inhibition studies  
In a study with carbenoxolone it is observed, in healthy non-diabetic men, a small (although 
significant) increase in whole body insulin sensitivity (Hollis & Huber, 2011; Walker et al., 
1995a). Walker et al. infered that carbenoxolone, by inhibiting hepatic 11ǃ-HSD1 and reducing 
intra-hepatic cortisol concentration, increases hepatic insulin sensitivity and decreases hepatic 
glucose production (Walker et al., 1995b). Further developing their research on carbenoxolone 
11ǃ-HSD1 inhibition, Walker et al. report decreased glucagon-stimulated glucose production 
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and glycogenolysis in T2DM men (non-obese normotensive, treated with diet alone), but not 
in healthy subjects, and decreased total cholesterol in healthy subjects, but not in T2DM 
patients. Carbenoxolone has no effect on gluconeogenesis, peripheral glucose uptake or 
insulin-mediated reduction of plasma FFA (Andrews et al., 2003). So, as just described, 
carbenoxolone enhances hepatic insulin sensitivity in healthy men and in non-obese 
normotensive T2DM. However, Sandeep et al. describe later, in non-diabetic obese men, a 
highly effective inhibition of whole-body 11-HSD turnover by carbenoxolone, but without 
inhibiting the conversion of cortisone to cortisol in SAT or modifying insulin sensitivity 
(Sandeep et al., 2005). Nevertheless, 11ǃ-HSD1 inhibition in AT by carbenoxolone has been 
reported. After both a single dose and posterior 72 h of continuous treatment with 
carbenoxolone, in healthy male volunteers, Tomlinson et al. observe a decrease not only on 
serum cortisol generation, after oral administration of cortisone acetate (although only 
significantly for continuous treatment), but also on cortisol concentrations, after oral cortisone 
acetate, and glycerol concentrations, after oral prednisone, both within SAT interstitial fluid (in 
the latter location being indicative of inhibition of GC-mediated lipolysis) (Tomlinson et al., 
2007). It is important to mention that 11-HSD2 inhibition, with licorice or carbenoxolone, can 
lead to cortisol-dependent mineralocorticoid excess, with hypertension, sodium retention, 
hypokalemia and fluid retention (Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; 
Gathercole & Stewart, 2010; Palermo et al., 2004; Stewart et al., 1990; Stewart et al., 1987). 11ǃ-
HSD2 is expressed principally in the distal nephron, where it inactivates cortisol to cortisone 
and thereby protects MR from cortisol (Andrews et al., 2003; Edwards et al., 1988; Ferrari, 2010; 
Funder et al., 1988; Palermo et al., 2004). PF-915275 is a potent and selective 11ǃ-HSD1 
inhibitor, without adverse side effects in a wide range of orally tested doses, that is selective 
for the human and primate enzymes (Bhat et al., 2008; Courtney et al., 2008). A modest 
pharmacodynamic effect of PF-915275 on 11ǃ-HSD1 activity in the healthy human liver is 
reported, but experiments to assess its inhibitory effect in the AT have not been performed 
(Courtney et al., 2008; Hollis & Huber, 2011). So far, to our knowledge, there are no reports of 
PF-915275 activity in patients with T2DM or MetSyn (or any of the associated components). 
Bhat et al. showed, in normal cynomolgus monkeys, that PF-915275 dose-dependently inhibits 
11ǃ-HSD1-mediated conversion of prednisone to prednisolone and reduces insulin levels 
(Bhat et al., 2008). Hollis et al. reviewed the clinical results obtained with the selective 11ǃ-
HSD1 inhibitor INCB13739. In patients with T2DM inadequately controlled with metformin, 
INCB13739 treatment achieves significant reductions in hemoglobin A1c, fasting plasma 
glucose and HOMA-IR (homeostasis model assessment-IR), and improves hyperlipidemia and 
hypertriglyceridemia (when present). Adverse events (occurring in ≥ 3%: nasopharyngitis, 
headache, diarrhea, cough, nausea, arthralgia and upper respiratory tract infection) were 
similar across all treatment groups. Interestingly, those positive effects are observed primarily 
in subjects categorized as obese (BMI > 30 kg/m²) and not in subjects categorized as 
overweight (BMI ≤ 30 kg/m²), underscoring the likely importance of AT 11ǃ-HSD1 activity to 
the cardiometabolic sequelae of obesity (Hollis & Huber, 2011; Rosenstock et al., 2010). Feig et 
al. showed that 11ǃ-HSD1 selective inhibition with MK-0916 is generally well tolerated in 
patients with T2DM and MetSyn (NCEP ATP III-defined) (Feig et al., 2011; S. Shah et al., 2011). 
Although no significant improvement in fasting plasma glucose is observed with MK-0916 
compared to placebo, modest improvements in hemoglobin A1c, body weight and blood 
pressure are observed (Feig et al., 2011). These patients were only mildly hypertensive, with 
55% receiving ongoing anti-hypertensive therapy, and yet treatment with MK-0916 led to 
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reductions from baseline of 7.9 and 5.4 mmHg in systolic and diastolic blood pressure, 
respectively, relative to placebo (Feig et al., 2011; S. Shah et al., 2011). Further developing the 
research on 11ǃ-HSD1 selective inhibition, Shah et al. reported that, in overweight-to-obese 
hypertensive patients, reduction in trough sitting diastolic blood pressure with MK-0736 is not 
statistically significant. Nonetheless, MK-0736 is well tolerated and appears to modestly 
improve other blood pressure endpoints as well as LDL-cholesterol and body weight. The 24 h 
ambulatory blood pressure measurements data (from the subset of patients who participated 
in ambulatory blood pressure measurements) suggest that MK-0736 has blood pressure-
lowering efficacy over a 24 h period not adequately represented by measuring sitting diastolic 
blood pressure and sitting systolic blood pressure, notably a greater blood pressure-lowering 
effect during daytime than during night-time (S. Shah et al., 2011). 11ǃ-HSD1 inhibitors may 
improve a number of metabolic disturbances, unlike current available anti-diabetic 
compounds, that occur in obesity, T2DM and/or MetSyn patients, as seen from genetically 
engineered animal studies (Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004) as 
well as from animal (Alberts et al., 2002; Alberts et al., 2003; Barf et al., 2002; Cooper & Stewart, 
2009; Feng et al., 2010; Gathercole & Stewart, 2010; Hermanowski-Vosatka et al., 2005; 
Johansson et al., 2008; J. Liu et al., 2011; Livingstone & Walker, 2003; Morgan et al., 2009; Park 
et al., 2011; Taylor et al., 2008; Véniant et al., 2010; S. J. Wang et al., 2006; X. Zhang et al., 2009b) 
and human 11ǃ-HSD1 inhibition studies (Andrews et al., 2003; Courtney et al., 2008; Feig et al., 
2011; Gathercole & Stewart, 2010; Hollis & Huber, 2011; Morton, 2010; Rosenstock et al., 
2010; Sandeep et al., 2005; S. Shah et al., 2011; Tomlinson et al., 2007; van Raalte et al., 2009; 
Walker et al., 1995a; Wamil & Seckl, 2007). Taking this into account, pharmacological 
inhibition of 11ǃ-HSD1 to lower intracellular cortisol concentrations in the liver and AT, 
without altering circulating cortisol concentrations or responses to stress, is an exciting 
potential therapy in those conditions and likely to be most effective in obese T2DM patients 
(Andrews et al., 2003; Courtney et al., 2008; Feig et al., 2011; Gathercole & Stewart, 2010; 
Hollis & Huber, 2011; Morton, 2010; Rosenstock et al., 2010; Sandeep et al., 2005; S. Shah et 
al., 2011; R.  Stimson et al., 2011; Tomlinson et al., 2007; van Raalte et al., 2009; Walker et al., 
1995a; Wamil & Seckl, 2007). 
8. Conclusion 
According to the rising prevalence of the MetSyn and the burden of its associated 
cardiometabolic complications, the study of the mechanisms of disease as well as of possible 
prophylactic and therapeutic approaches is becoming increasingly necessary. The 
recognition of the involvement of GCs and 11ǃ-HSD1, as likely etiological factors, adds new 
avenues for MetSyn management. Lately, research focusing on 11ǃ-HSD1 inhibition has 
shown promising results. The role of dietary patterns on MetSyn development and of 
dietary components on 11ǃ-HSD1 modulation for the prevention and/or treatment of 
metabolic disorders is now starting to be unraveled and may be a worthwhile investigation. 
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